Citi raised the firm’s price target on Krystal Biotech (KRYS) to $176 from $155 and keeps a Neutral rating on the shares. KB801 is an underappreciated asset that may be able to show differentiation from commercial Oxervate given its ‘s better dosing regimen and potentially superior NGF protein duration, and the firm has incorporated the KB801 program into its model, assigning it a 25% probability of success, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Promising Market Potential and Innovative Approach Drive Buy Rating for Krystal Biotech’s Gene Therapy KB801
- Krystal Biotech Begins Phase 1/2 Trial for KB801
- Krystal Biotech announces first patient dosed in Phase 1/2 trial of KB801
- Krystal Biotech reports assay results from Phase 2 drill program in Namibia
- 3 Best Stocks to Buy Now, 7/1/2025, According to Top Analysts